文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Management of cognitive impairment associated with post-COVID-19 syndrome: recommendations for primary care.

作者信息

Zifko Udo, Guendling Katja, Seet Raymond, Kasper Siegfried

机构信息

Rudolfinerhaus private clinic GmbH, Rudolfinerhaus, Vienna, Austria.

Internal Medicine Family Practice, Bad Camberg, Germany.

出版信息

Front Pharmacol. 2024 Apr 22;15:1338235. doi: 10.3389/fphar.2024.1338235. eCollection 2024.


DOI:10.3389/fphar.2024.1338235
PMID:38711990
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11072190/
Abstract

Although post-COVID-19 syndrome (PCS) with cognitive impairment is increasingly encountered in primary care, evidence-based recommendations for its appropriate management are lacking. A systematic literature search evaluating the diagnosis and treatment of cognitive impairment associated with PCS was conducted. Practical recommendations for the management of PCS-associated cognitive impairment in primary care are summarized, based on an evaluation of pharmacological plausibility and clinical applications. Currently, the pathology of cognitive impairment associated with PCS remains unclear with no high-quality data to support targeted interventions. Existing treatment approaches are directed towards symptom relief where counseling on the chronicity of the disease and regular reassessments at 4- to 8-week intervals is considered reasonable. Patients should be informed and encouraged to adopt a healthy lifestyle that centers around balanced nutrition and appropriate physical activities. They may also benefit from the intake of vitamins, micronutrients, and probiotics. The administration of extract could offer a safe and potentially beneficial treatment option. Other non-pharmacological measures include physiotherapy, digitally supported cognitive training, and, if indicated, ergotherapy or speech therapy. In most patients, symptoms improve within 8 weeks. If serious, ambiguous, or when new symptoms occur, specialized diagnostic measures such as comprehensive neurocognitive testing or neuroimaging should be initiated. Very few patients would require inpatient rehabilitation. PCS with cognitive impairment is a debilitating condition that could affect daily functioning and reduce work productivity. Management in primary care should adopt a multidisciplinary approach, centering around physical, cognitive, and pharmacological therapies.

摘要

相似文献

[1]
Management of cognitive impairment associated with post-COVID-19 syndrome: recommendations for primary care.

Front Pharmacol. 2024-4-22

[2]

2020-2

[3]

2008-6

[4]
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.

Cochrane Database Syst Rev. 2022-2-1

[5]

2013-11

[6]
Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation.

Health Technol Assess. 2020-9

[7]
Strategies for the use of Ginkgo biloba extract, EGb 761 , in the treatment and management of mild cognitive impairment in Asia: Expert consensus.

CNS Neurosci Ther. 2021-2

[8]
Ginkgo biloba for cognitive impairment and dementia.

Cochrane Database Syst Rev. 2009-1-21

[9]
Ginkgo biloba for cognitive impairment and dementia.

Cochrane Database Syst Rev. 2002

[10]
Ginkgo biloba for cognitive impairment and dementia.

Cochrane Database Syst Rev. 2007-4-18

引用本文的文献

[1]
Exploring the experiences of cognitive symptoms in Long COVID: a mixed-methods study in the UK.

BMJ Open. 2025-1-25

[2]
Cognitive outcomes and psychological symptoms in an Italian cohort with post-acute COVID-19 condition (PACC).

Heliyon. 2024-10-16

本文引用的文献

[1]
Clinical Evidence on the Potential Beneficial Effects of Diet and Dietary Supplements against COVID-19 Infection Risk and Symptoms' Severity.

Med Sci (Basel). 2024-2-17

[2]
Multi-target drugs for the treatment of cognitive impairment and fatigue in post-COVID syndrome: focus on Ginkgo biloba and Rhodiola rosea.

J Neural Transm (Vienna). 2024-3

[3]
Neuroprotective Agents with Therapeutic Potential for COVID-19.

Biomolecules. 2023-10-27

[4]
The effect of donepezil hydrochloride on post-COVID memory impairment: A randomized controlled trial.

J Clin Neurosci. 2023-12

[5]
Evaluation and treatment approaches for neurological post-acute sequelae of COVID-19: A consensus statement and scoping review from the global COVID-19 neuro research coalition.

J Neurol Sci. 2023-11-15

[6]
[S1 guidelines for the management of postviral conditions using the example of post-COVID-19].

Wien Klin Wochenschr. 2023-7

[7]
What do we mean by long COVID? A scoping review of the cognitive sequelae of SARS-CoV-2 infection.

Eur J Neurol. 2023-12

[8]
Persistent endothelial dysfunction in post-COVID-19 syndrome and its associations with symptom severity and chronic inflammation.

Angiogenesis. 2023-11

[9]
Post-COVID-19 Syndrome in Neurology Patients: A Single Center Experience.

Pathogens. 2023-6-2

[10]
Effect of famotidine on cognitive and behavioral dysfunctions induced in post-COVID-19 infection: A randomized, double-blind, and placebo-controlled study.

J Psychosom Res. 2023-9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索